Judge Keeps Fraud Claims Against GSK Alive In Zofran MDL

Law360, New York (April 24, 2017, 5:35 PM EDT) -- A Massachusetts federal judge on Monday declined to nix fraud-based claims from multidistrict litigation alleging that GlaxoSmithKline PLC’s anti-nausea drug Zofran is linked to birth defects, saying that claims about the drug’s labeling are sufficiently specific to pass muster even though he found the suit's marketing-campaign allegations too broad.

According to U.S. District Judge  F. Dennis Saylor IV, consumers say GSK knowingly misrepresented the safety of taking Zofran during pregnancy in its advertising and marketing campaigns, but they haven't provided a specific allegation — either in...
To view the full article, register now.




Case Information

Case Title

In Re: Zofran (Ondansetron)Products Liability Litigation

Case Number




Nature of Suit

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability


F. Dennis Saylor, IV

Date Filed

October 13, 2015

Law Firms


Government Agencies

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.